Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other Accumulated Expenses (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Other Accumulated Expenses for 7 consecutive years, with $120.2 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 263.53% to $120.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $120.2 million through Dec 2025, up 263.53% year-over-year, with the annual reading at $120.2 million for FY2025, 263.53% up from the prior year.
  • Other Accumulated Expenses hit $120.2 million in Q4 2025 for BridgeBio Pharma, up from $92.7 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $120.2 million in Q4 2025 to a low of $4.7 million in Q4 2023.
  • Historically, Other Accumulated Expenses has averaged $29.5 million across 5 years, with a median of $21.2 million in 2021.
  • Biggest five-year swings in Other Accumulated Expenses: surged 96159.09% in 2021 and later crashed 82.86% in 2022.
  • Year by year, Other Accumulated Expenses stood at $30.3 million in 2021, then plummeted by 82.86% to $5.2 million in 2022, then fell by 10.27% to $4.7 million in 2023, then soared by 610.14% to $33.1 million in 2024, then soared by 263.53% to $120.2 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for BBIO at $120.2 million in Q4 2025, $92.7 million in Q3 2025, and $65.9 million in Q2 2025.